ProCognia Deals With SBH and Health Canada

Glycoanalysis developer ProCognia (TASE:PRCG) has signed a strategic collaboration and co-promotion agreement with Boston-based biotechnology services provider SBH Sciences Inc. The companies provide complementary services to the biopharmaceutical and pharmaceutical industries, and they will offer joint sales and marketing activities for these services. SBH Sciences will also serve as a local center for Procognia’s glycosylation analysis services, and will be responsible for shipment of samples for analysis to Procognia’s main facility in Israel.

ProCognia also signed a deal to provide glycosylation analysis products and services to the Biologics and Genetic Therapies Directorate of Health Canada, for research on biotherapeutic products.

Written by

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam libero diam, elementum eget porttitor at, tincidunt at nulla.